Genmab AS ADR GMAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
-
AbbVie, Genmab's Lymphoma Treatment Meets Primary Endpoint in Phase 3 Trial
-
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
-
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
-
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
-
AbbVie, Genmab Lymphoma Treatment Shows Improved Progression-Free Survival
-
Months after cancer drug trial, Merus agrees to be bought at 41% premium
-
Genmab Receives FDA Breakthrough Therapy Designation for Advanced Endometrial Cancer Treatment
Trading Information
- Previous Close Price
- $27.91
- Day Range
- $27.98–28.55
- 52-Week Range
- $21.00–35.43
- Bid/Ask
- $28.36 / $28.37
- Shares Outstanding
- 613.94M
- Market Cap
- $17.41B
- Volume/Avg
- 871,699 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 16.72
- Price/Sales
- 4.56
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 3,088
- Website
- https://www.genmab.com
Competitors
Valuation
|
Metric
|
GMAB
|
4502
|
INCY
|
|---|---|---|---|
Price/Earnings (Normalized) | 16.93 | 27.37 | 15.76 |
Price/Book Value | 3.10 | 1.14 | 4.17 |
Price/Sales | 4.61 | 1.87 | 4.44 |
Price/Cash Flow | 20.81 | 11.69 | 11.07 |
Price/Earnings
GMAB
4502
INCY
Financial Strength
|
Metric
|
GMAB
|
4502
|
INCY
|
|---|---|---|---|
Quick Ratio | 2.17 | 0.53 | 3.40 |
Current Ratio | 2.18 | 1.09 | 3.68 |
Interest Coverage | 6.45 | −0.08 | 710.24 |
Quick Ratio
GMAB
4502
INCY
Profitability
|
Metric
|
GMAB
|
4502
|
INCY
|
|---|---|---|---|
Return on Assets (Normalized) | 12.45% | 5.53% | 23.45% |
Return on Equity (Normalized) | 20.24% | 11.31% | 32.44% |
Return on Invested Capital (Normalized) | 14.93% | 7.70% | 30.19% |
Return on Assets
GMAB
4502
INCY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^zf!w? | LOCK|#Ymmw | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$d$%$$^ | LOCK|^&lN | $71B | |||
| argenx SE ADR
ARGX
| LOCK|Wjw#j# | LOCK|<YV | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$>%KNK | LOCK|L< | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@m%&#yc | LOCK|&#M& | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|vJ$#&L> | LOCK|%k&L | $26B | |||
| Moderna Inc
MRNA
| LOCK|Ht&kyR> | LOCK|zD | $25B | |||
| Incyte Corp
INCY
| LOCK|d#dT>#> | LOCK|Wyq | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|rk!Gv! | LOCK|PZn | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|XW^S>! | LOCK|&cM | $16B |
United States